There are currently 127 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Feasibility Pilot of Accelerated Stimulation With TMS for Treatment of Major Depressive Disorder (FAST-MDD)
NCT06961851
Recruiting
This is a mixed-methods study that includes three steps. The first is a focus group to collect opinions and feedback about implementation of aTMS among clinicians, technicians, nurses, and other clinical staff at the St. Louis Park (SLP) clinic who are experienced with delivering TMS. The second is the delivery of a set of questionnaires delivered to TMS patients at the SLP clinic who are awaiting the start of their TMS series. The third is the delivery of aTMS utilizing the MagVenture TMS devic... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/11/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Major Depressive Disorder
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/11/2025
Locations: IMA Clinical Research Phoenix, Phoenix, Arizona +45 locations
Conditions: Major Depressive Disorder
Register for Updates
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/08/2025
Locations: Neumora Investigator site, Huntsville, Alabama +165 locations
Conditions: Major Depressive Disorder
Register for Updates
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
NCT06564818
Recruiting
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/06/2025
Locations: Scottsdale Research Institute, Phoenix, Arizona +44 locations
Conditions: Major Depressive Disorder
Register for Updates
Decoding and Modulating Affective Brain States
NCT05437705
Recruiting
The research study is being conducted to study brain patterns of negative emotion and develop personalized brain stimulation protocols to disrupt these patterns with transcranial magnetic stimulation (TMS). First, we will use functional Magnetic Resonance Imaging (fMRI) data to generate a negative affect map for each subject. Then, we will try a variety of repetitive transcranial magnetic stimulation (rTMS) sequences while inside the MRI scanner to determine the optimal and least optimal rTMS fr... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/06/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Rumination, Major Depressive Disorder, Anxiety
Register for Updates
Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS)
NCT06979154
Recruiting
The purpose of this study is to develop the safety, feasibility, and tolerability of a personalized transcranial alternating current stimulation (tACS) approach in antenatal depression.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
08/06/2025
Locations: Carolina Center for Neurostimulation, Chapel Hill, North Carolina
Conditions: Antenatal Depression, Major Depressive Disorder, Major Depressive Disorder in Pregnancy, Healthy Controls
Register for Updates
Psilocybin-assisted CBT for Depression
NCT05227612
Recruiting
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study has two phases. Phase I will involve an o... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
08/04/2025
Locations: UCLA Semel Institute, Los Angeles, California
Conditions: Major Depressive Disorder
Register for Updates
5-HTP and Creatine for Depression R33 Phase
NCT05895747
Recruiting
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/04/2025
Locations: University of Utah Department of Psychiatry, Salt Lake City, Utah
Conditions: Major Depressive Disorder
Register for Updates
Mindfulness Engaged Neurostimulation for Depression
NCT06399406
Recruiting
Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermitten... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/01/2025
Locations: University of California San Diego, La Jolla, California
Conditions: Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
Register for Updates
Positive Processes and Transition to Health (PATH)
NCT06093906
Recruiting
The R33 will be a randomized controlled trial to replicate changes in the targets (unproductive processing, avoidance, reward deficits) from the R61 phase in a larger sample of 135 participants who have experienced a destabilizing life event involving profound loss or threat, report persistent stressor-related symptoms of PTSD and/or depression, and are elevated on symptoms related to 2 of the 3 therapeutic targets. Additionally, this study will examine Positive Processes and Transition to Healt... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2025
Locations: University of Delaware, Newark, Delaware +2 locations
Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder
Register for Updates
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401
Recruiting
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Neurocrine Clinical Site, Little Rock, Arkansas +17 locations
Conditions: Major Depressive Disorder
Register for Updates
RESISTance Exercise for Depression Trial
NCT06110897
Recruiting
Depression is a leading cause of disability worldwide and current treatments are ineffective for many people. This trial will investigate the efficacy of a 16-week high vs low dose resistance exercise training program for the treatment of Major Depressive Disorder (MDD) in 200 adults.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/28/2025
Locations: Iowa State University, Ames, Iowa +1 locations
Conditions: Major Depressive Disorder
Register for Updates